Clinical Trial Update: Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is investigating cabazitaxel in combination with 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer; the study is cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Jevtana (cabazitaxel)
• Pluvicto (lutetium-177 PSMA-617)

Snippet

Sponsor: Peter MacCallum Cancer Centre, Australia | Conditions: Metastatic Castration-resistant Prostate Cancer, mCRPC | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING